Company Overview
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 17.8% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $149.16M (+99.2% YoY); net profit $-39.00M.
- Trailing 12 Months Year-on-year growth — revenue +9.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.77% |
| 1 Year: | 9.10% |
Stock Price Performance
| 1 Year: | -45.48% |
| 6 Months: | +25.60% |
| 3 Months: | +16.57% |
| 1 Month: | -25.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)42.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 17.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 45.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STIM Neuronetics, Inc. R2KPHARMA | 2.11 | -4.91 | $160.78M | 0.00% | -28.31% | -116.10% | 17.77% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 10.15M | 13.25M | 13.74M | - | 12.73M | 16.57M | 16.00M | - | 11.48M | 9.74M | 12.45M | - | 12.29M | 14.20M | 13.80M | 14.18M | 16.33M | 16.50M | 15.54M | 17.61M | 17.88M | 17.42M | 16.45M | 18.53M | 31.98M | 38.11M | 37.30M | 34.45M |
| Gross Profit | 5.99M | 7.81M | 7.86M | 9.15M | 7.70M | 10.01M | 10.70M | 11.92M | 9.92M | 12.40M | 11.81M | 13.14M | 8.66M | 7.42M | 9.79M | 11.82M | 10.07M | 11.45M | 10.65M | 10.70M | 12.29M | 12.93M | 11.40M | 12.77M | 11.76M | 13.09M | 12.18M | 14.00M | 15.74M | 17.76M | 17.11M | 16.15M |
| Operating Income | -3.99M | -2.58M | -2.81M | -4.23M | -4.61M | -5.24M | -4.33M | -5.66M | -7.06M | -6.61M | -6.33M | -6.94M | -10.37M | -6.86M | -2.42M | -2.66M | -6.91M | -6.56M | -7.18M | -10.13M | -9.80M | -7.45M | -9.91M | -7.35M | -8.87M | -6.86M | -8.51M | -7.73M | -11.01M | -8.06M | -7.32M | -8.99M |
| Net Income | -4.51M | -2.87M | -3.75M | -4.92M | -5.50M | -7.50M | -4.96M | -6.14M | -7.53M | -7.09M | -6.87M | -7.55M | -12.61M | -7.76M | -3.42M | -3.66M | -7.88M | -7.53M | -8.15M | -10.84M | -10.42M | -7.61M | -10.52M | -4.90M | -9.39M | -7.87M | -9.83M | -13.34M | -12.68M | -10.12M | -9.04M | -10.79M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.41 | -0.18 | - | -0.31 | -0.29 | -0.31 | -0.41 | -0.39 | -0.28 | -0.38 | -0.17 | -0.33 | -0.27 | -0.33 | -0.44 | -0.21 | -0.15 | -0.13 | -0.16 |
| R&D Expense | 2.03M | 2.15M | 1.84M | 1.92M | 1.55M | 2.33M | 2.12M | 2.22M | 2.79M | 3.22M | 3.49M | 4.25M | 3.02M | 2.12M | 1.95M | 2.11M | 2.31M | 2.29M | 1.57M | 1.80M | 2.04M | 2.35M | 2.79M | 2.36M | 2.15M | 2.35M | 2.23M | 2.42M | 1.62M | 1.80M | 1.50M | 1.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.23M | 40.43M | 52.78M | 62.66M | 49.24M | 55.31M | 65.21M | 71.35M | 74.89M | 149.16M |
| Gross Profit | 27.61M | 30.80M | 40.33M | 47.27M | 37.69M | 43.66M | 49.72M | 51.70M | 54.16M | 72.31M |
| Operating Income | -9.34M | -13.61M | -19.83M | -26.93M | -22.31M | -27.56M | -35.11M | -30.55M | -34.56M | -31.44M |
| Net Income | -11.23M | -16.06M | -24.10M | -29.04M | -27.45M | -31.19M | -37.16M | -30.19M | -43.71M | -39.00M |
| Diluted EPS | - | - | - | -1.58 | -1.46 | -1.22 | -1.38 | -1.05 | -1.38 | -0.59 |
| R&D Expense | 8.22M | 7.94M | 8.23M | 13.75M | 9.20M | 7.92M | 9.34M | 9.52M | 12.77M | 6.58M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 38.94M | 117.02M | 100.17M | 78.66M | 141.22M | 116.88M | 115.83M | 140.90M | 141.55M |
| Total Equity | -166.12M | -177.12M | -192.65M | 71.04M | 47.85M | 25.49M | 85.17M | 57.06M | 34.19M | 27.71M | 22.38M |
| Cash & Equivalents | - | - | 29.15M | 104.58M | 75.71M | 48.96M | 94.14M | 70.34M | 59.68M | 18.46M | 28.13M |
| Long Term Debt | - | - | 29.56M | 30.39M | 19.90M | 34.62M | 35.34M | 22.83M | 59.28M | 55.15M | 65.81M |
| Total Liabilities | - | - | 44.45M | 45.98M | 52.32M | 53.16M | 56.05M | 59.82M | 81.64M | 109.10M | 115.31M |
| Current Liabilities | - | - | 11.99M | 13.56M | 27.69M | 13.68M | 15.70M | 33.20M | 19.81M | 31.27M | 30.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.54M | -11.14M | -20.59M | -30.48M | -28.39M | -27.98M | -30.74M | -32.04M | -31.00M | -20.37M |
| Investing Cash Flow | -324.00K | -594.00K | -1.01M | -813.00K | -730.00K | -9.84M | 6.73M | -1.32M | -2.41M | -801.00K |
| Financing Cash Flow | 4.90M | 23.84M | 97.04M | 2.42M | 2.37M | 83.01M | 207.00K | 22.70M | -6.81M | 35.85M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 80.7% | 76.2% | 76.4% | 75.4% | 76.5% | 78.9% | 76.3% | 72.5% | 72.3% | 48.5% |
| Operating Margin % | -27.3% | -33.7% | -37.6% | -43.0% | -45.3% | -49.8% | -53.8% | -42.8% | -46.2% | -21.1% |
| Net Margin % | -32.8% | -39.7% | -45.7% | -46.4% | -55.7% | -56.4% | -57.0% | -42.3% | -58.4% | -26.1% |
| ROE % | 6.3% | 8.3% | -33.9% | -60.7% | -107.7% | -36.6% | -65.1% | -88.3% | -157.8% | -174.3% |
| ROCE % | - | -50.5% | -19.2% | -37.2% | -34.3% | -22.0% | -42.0% | -31.8% | -31.5% | -28.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Madryn Asset Management, LP | 24.33% | 18.54M | $39.49M |
| 2 | UBS Group AG | 2.99% | 2.28M | $4.85M |
| 3 | Wexford Capital LP | 2.63% | 2.00M | $4.27M |
| 4 | FourWorld Capital Management, LLC | 2.29% | 1.74M | $3.72M |
| 5 | Lane Generational LLC | 2.14% | 1.63M | $3.48M |
| 6 | Vanguard Capital Management LLC | 1.98% | 1.51M | $3.21M |
| 7 | Masters Capital Management, LLC | 1.31% | 1.00M | $2.13M |
| 8 | AdvisorShares Investments, LLC | 0.97% | 742.79K | $1.58M |
| 9 | Ikarian Capital, LLC | 0.92% | 701.18K | $1.49M |
| 10 | Blackrock Inc. | 0.78% | 596.62K | $1.27M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for STIM
Neuronetics, Inc. Estimates – NASDAQ:STIM - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5nak9DaXFDREVwRVpTMV8xZllVZ2s1bHluQXBIbmVPb0J6dDhxeWp0WUpIcXN3NzZURzd0dnhNUHBMaFpWaHlNVE1UNXUyby1wcXhOYUNFNGtCVU9FR2dOS0ZMN2hNUUFVQjZUaXdRYXlaT0dPZHdoeQ?oc=5" target="_blank">Neuro…
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQTm9ab1dlYnQ4NkI5MF90QzEyYTg5RW5CSzI1YlNZZ1I2cW9jMzVKVjNsOTdMa1lSRHpQaGtMS0pnUHpwaW40d3htWjFGM0dncXhJOGhXV245Y2gwLU1zNzFGZXZjLThCU1FpSUFYS0xoY0dEUkdPQzdNTmNndUFCTFF6WjA0YXFKQlB6Y0…
Neuronetics (STIM) Stock Price, News & Analysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTFBQN2VSME9HX0ZCa2h2dHltbFlreUFOQTByeXRlU1hFcUxhQjRtSHZOM1JyYzRyVWdpNjI0MnpiODVZLXhpcDZYX0RhYjRiOEsyNkdN?oc=5" target="_blank">Neuronetics (STIM) Stock Price, News & Analysis</a>&nbs…
Neuronetics: Transforming From Device Manufacturer To Psychedelic Infrastructure (STIM) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPejh6VTU4UkNFbHc4YXV1djd4ZGtfeE9jazRrMmdBWnNIZ0N1V1pldUNfTEJIcDliOU55MXNJUlhDeUlaU0lObE53NG9Cc2JkNXpFb2tXdVMwTmlaajdJNDRRWDE1MzRtZE1ucXRDVVV4XzdUdkRnLTdvY3NUZEJRdWxGY2Y4bXo3WElaWV…
Why Is STIM Stock Rallying 16% After-Hours? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPX0RpVHd6b1NmLWtFUlhQOUtGVVIxWFFmVnF0bWxoMzdudDlydl9md0JfblZjdUdtS0VHNlc5ZzRsdlUxejhNaTZfSTc2UUtQcy1PQWtucjNYU1J5bFZOeTZDX2s4b05KbW1PRXoyZU13Wnh4SURMRHpuNTE4djV3MGdsUVo3aWotX3JHal…
$STIM stock is up 37% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQMVVzYmZPVmh6cjRQRklod2VWZTFwVGhaSm0xZkF6dldXNFBrMnJYeTBxV3V6cllxYUQwZEFGX2p5Vkg4eFFlTU9IY19jSzd4WWg4MzhJT3hUYjZGSjJUb2JzZW9vazNOdFVQZUJRWm55WVFOQVFXRTlYdlV5ZFBqZUlSVkFfMVlJNUJ3MW…
STIM — Frequently Asked Questions
What is the current share price of Neuronetics, Inc. (STIM)?
As of 2026-10-23 16:27 PDT, Neuronetics, Inc. (STIM) trades at $2.11 on NasdaqGM. Its 52-week range is $1.18 to $3.87.
What is the market capitalisation of STIM?
Neuronetics, Inc. (STIM) has a market capitalisation of $160.78M on NasdaqGM.
What is the P/E ratio of STIM?
STIM trades at a trailing price-to-earnings (P/E) ratio of -4.91. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 12.39.
What is the return on equity (ROE) of STIM?
STIM has a return on equity (ROE) of -116.10%. Its return on capital employed (ROCE) is -28.31%.
Is STIM a good stock to buy?
This page provides a data-driven analysis of Neuronetics, Inc. (STIM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.